Quintiles Transitional Holdings Inc. (NYSE:Q)‘s stock had its “outperform” rating reiterated by equities research analysts at Credit Suisse Group in a report released on Monday, October 16th, The Fly reports. They currently have a $110.00 price objective on the medical research company’s stock, up from their prior price objective of $98.00. Credit Suisse Group’s price target points to a potential upside of 4.27% from the company’s current price.
A number of other equities analysts have also recently commented on Q. Citigroup Inc. reaffirmed a “neutral” rating and issued a $96.00 target price (up from $87.00) on shares of Quintiles Transitional Holdings in a report on Wednesday, June 28th. Robert W. Baird raised Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $76.00 to $93.00 in a report on Friday, July 7th. Barclays PLC reaffirmed an “overweight” rating and issued a $98.00 target price (up from $90.00) on shares of Quintiles Transitional Holdings in a report on Monday, July 17th. Zacks Investment Research raised Quintiles Transitional Holdings from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a report on Thursday, July 27th. Finally, William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their price target for the company from $70.10 to $93.42 in a report on Friday, August 4th. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $94.77.
Shares of Quintiles Transitional Holdings (NYSE Q) opened at 105.50 on Monday. The company has a market capitalization of $22.84 billion, a P/E ratio of 305.80 and a beta of 0.62. Quintiles Transitional Holdings has a 12 month low of $70.10 and a 12 month high of $106.65. The company’s 50 day moving average price is $97.06 and its 200 day moving average price is $90.20.
Quintiles Transitional Holdings (NYSE:Q) last released its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.05. The firm had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The company’s revenue was up 77.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.00 EPS. Analysts expect that Quintiles Transitional Holdings will post $4.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/credit-suisse-group-reiterates-outperform-rating-for-quintiles-transitional-holdings-inc-q.html.
In other news, insider Ari Bousbib sold 92,160 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $90.35, for a total transaction of $8,326,656.00. Following the completion of the sale, the insider now owns 1,082,919 shares of the company’s stock, valued at $97,841,731.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 20,000 shares of Quintiles Transitional Holdings stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $90.28, for a total transaction of $1,805,600.00. Following the sale, the insider now directly owns 46,826 shares of the company’s stock, valued at approximately $4,227,451.28. The disclosure for this sale can be found here. Insiders have sold 14,208,382 shares of company stock valued at $1,362,839,475 in the last 90 days. Company insiders own 6.40% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. IFC Holdings Incorporated FL bought a new position in Quintiles Transitional Holdings in the third quarter worth approximately $296,000. Paragon Capital Management Ltd bought a new position in Quintiles Transitional Holdings in the third quarter worth approximately $624,000. Pictet Asset Management Ltd. raised its stake in Quintiles Transitional Holdings by 35.3% in the third quarter. Pictet Asset Management Ltd. now owns 73,423 shares of the medical research company’s stock worth $6,980,000 after buying an additional 19,139 shares in the last quarter. Aperio Group LLC raised its stake in Quintiles Transitional Holdings by 7.5% in the third quarter. Aperio Group LLC now owns 66,830 shares of the medical research company’s stock worth $6,354,000 after buying an additional 4,640 shares in the last quarter. Finally, Braun Stacey Associates Inc. bought a new position in Quintiles Transitional Holdings in the third quarter worth approximately $12,513,000. 93.27% of the stock is owned by institutional investors.
About Quintiles Transitional Holdings
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.